UK biotech Silence Therapeutics (AIM: SLN) has announced a number of changes to its management as it positions itself as a leading RNA technology company.
The UK-based company, which focuses on the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, has made changes to its board, set up a technology advisory board, and made a senior scientific appointment.
David Ellam is to become Silence’s chief financial officer and a director from July 18. His previous senior finance roles have been with companies in the USA and the UK, most recently with US biotech BioMarin Pharmaceutical (Nasdaq: BMRN).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze